Leash Bio
Transforming drug design with a rich dataset built by screening millions of compounds against thousands of proteins to generate billions of data points, ideal for training advanced machine learning models.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | $9.3m | Seed | |
| Total Funding | 000k | ||
Related Content
A biotechnology company that is utilizing machine learning for drug discovery and design. The company, founded in 2021 and based in Salt Lake City, has developed a proprietary dataset of protein-molecule interactions. This dataset is used to power their machine learning models to accelerate the drug design process for the pharmaceutical and biotechnology industries.
Leash Bio operates on a B2B model, providing its platform to pharmaceutical and biotech companies to aid in their drug discovery efforts. The company has secured $9.3 million in a seed funding round from investors such as Mitsui Global Investment and Metaplanet. The team includes experienced professionals from the fields of data science and laboratory automation.
Keywords: drug discovery, machine learning, biotechnology, pharmaceutical, protein-molecule interactions, drug design, proprietary dataset, B2B, Salt Lake City, seed funding